Prosensa - About the company
Prosensa is an acquired company based in Leiden (Netherlands), founded in 2002. It operates as a RNA interference therapies for neuro disorders. Prosensa has raised $72.6M in funding from New Enterprise Associates. The company has 877 active competitors, including 291 funded and 210 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Human Longevity and Juno Therapeutics.
Company Details
Prosensa was focussed on the development of RNA-modulating therapeutics for the treatment of neuromuscular disorders. Its lead compound drisapersen was an oligonucleotide that alters the splicing of the dystrophin RNA transcript. The candidate was under 7 different programs in various stages of development for the treatment of Duchenne muscular dystrophy (DMD). In addition, it had preclinical products for Huntington's disease and myotonic dystrophy. In November 2014, it was acquired by BioMarin.
- Website
- www.prosensa.eu
- Social
Key Metrics
Founded Year
2002
Location
Leiden, Netherlands
Stage
Acquired
Total Funding
$72.6M in 4 rounds
Latest Funding Round
Investors
Ranked
177th among 877 active competitors
Similar Companies
Exit Details
Acquired by BioMarin Pharmaceutical (Nov 24, 2014)
Legal entities associated with Prosensa
Prosensa is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
Prosensa Holding N.V. CIN: 1574111 , United States, Active | $5M - $25M (As on Dec 08, 2014) | - | - |
Prosensa's acquisition details
Prosensa got acquired by BioMarin Pharmaceutical on Nov 24, 2014.
Click here to take a look at Prosensa's acquisition in detail
Sign up to download Prosensa's company profile
Prosensa's funding and investors
Prosensa has raised a total funding of $72.6M over 4 rounds. Its first funding round was on Feb 01, 2007. Its latest funding round was a Grant (prize money) round on Jun 27, 2014 for $*****. 1 investor participated in its latest round. Prosensa has 9 institutional investors.
Here is the list of recent funding rounds of Prosensa:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 27, 2014 | 3476612 | Grant (prize money) | 5822483 | 3642615 | 1953622 | 1492961 |
Jan 25, 2012 | 4130554 | Series C | 8586088 | 5591118 | 3491496 | |
Dec 17, 2008 | 3416871 | Series B | 3719370 | 2251805 | 9071506 |
Access funding benchmarks and valuations. Sign up today!View details of Prosensa's funding rounds and investors
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Prosensa's Competitors and alternates
Top competitors of Prosensa include Jazz Pharmaceuticals, Human Longevity and Juno Therapeutics. Here is the list of Top 10 competitors of Prosensa, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Human Longevity 2013, San Diego (United States), Series B | Provider of precision medicine, preventative health assessments, and longevity care | $409M | 76/100 | |
3rd | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
4th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 74/100 | |
5th | Pacira 2006, Parsippany Troy Hills (United States), Public | Developer of injectable non-opioid products for post-surgical pain control | $85M | 72/100 | |
6th |  UniQure 1998, Amsterdam (Netherlands), Public | Developer of gene-based therapies for patients with genetic or acquired diseases | $111M | 70/100 | |
7th | Intra-Cellular Therapies 2002, New York City (United States), Acquired | Developer of therapeutics for psychiatric and neurologic diseases | $80.9M | 70/100 | |
8th | Orchard Therapeutics 2015, London (United Kingdom), Acquired | Developer of gene therapies for treating rare diseases | $440M | 70/100 | |
9th | Castle Biosciences 2008, Friendswood (United States), Public | Provider of diagnostic devices for treating cancer | $62M | 70/100 | |
10th | Bluebird Bio 1992, Cambridge (United States), Acquired | Developer of gene therapies for severe genetic and rare diseases | $136M | 70/100 | |
177th | Prosensa 2002, Leiden (Netherlands), Acquired | RNA interference therapies for neuro disorders | $72.6M | 49/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Prosensa's competitors? Click here to see the top ones
Prosensa's Investments and acquisitions
Prosensa has made no investments or acquisitions yet.
News related to Prosensa
•
Sixfold Bioscience Announces Formation of Scientific Advisory BoardBusiness Wire•Aug 09, 2023•Prosensa, GSK, Sixfold Bioscience
•
Idinvest Partners | A partner for company growthIdinvest Partners•Actility, Foxconn Electronics, Ginko Ventures, Truffle Capital and 145 others
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Prosensa
Explore our recently published companies
- IDSYS - High Point based, 2016 founded, Unfunded company
- Saucon Source - Hellertown based, 2014 founded, Unfunded company
- WNYMedia - Tonawanda based, 2004 founded, Unfunded company
- Sun Extractions - Freehold based, 2021 founded, Unfunded company
- Tishomingo Public Schools - Tishomingo based, 2022 founded, Funding Raised company
- Grow Academy - Cairo based, 2026 founded, Seed company
